IO Biotech Announces Promising Results in Phase 3 Trial of Cylembio Plus KEYTRUDA for Advanced Melanoma, Plans FDA Meeting
Reuters
Aug 11
<a href="https://laohu8.com/S/IOBT">IO Biotech</a> Announces Promising Results in Phase 3 Trial of Cylembio Plus KEYTRUDA for Advanced Melanoma, Plans FDA Meeting
IO Biotech Inc. has announced clinical improvement in progression-free survival demonstrated in a pivotal Phase 3 trial of Cylembio® combined with KEYTRUDA® (Pembrolizumab) for the treatment of first-line advanced melanoma. The results showed that patients treated with the combination therapy achieved an improvement in progression-free survival compared to those treated with pembrolizumab monotherapy, with a hazard ratio of 0.77 and a median progression-free survival of 19.4 months versus 11.0 months. However, the study's primary endpoint narrowly missed the statistical significance threshold. IO Biotech plans to discuss the data with the United States Food and Drug Administration this fall to determine next steps for submission of a Biologics License Application. The company also plans to present more detailed results from the IOB-013 study at a future medical meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IO Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-177471), on August 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.